Literature DB >> 30912119

Pharmacodynamic Drug-Drug Interactions.

Jin Niu1, Robert M Straubinger1, Donald E Mager1.   

Abstract

Pharmacodynamic drug-drug interactions (DDIs) occur when the pharmacological effect of one drug is altered by that of another drug in a combination regimen. DDIs often are classified as synergistic, additive, or antagonistic in nature, albeit these terms are frequently misused. Within a complex pathophysiological system, the mechanism of interaction may occur at the same target or through alternate pathways. Quantitative evaluation of pharmacodynamic DDIs by employing modeling and simulation approaches is needed to identify and optimize safe and effective combination therapy regimens. This review investigates the opportunities and challenges in pharmacodynamic DDI studies and highlights examples of quantitative methods for evaluating pharmacodynamic DDIs, with a particular emphasis on the use of mechanism-based modeling and simulation in DDI studies. Advancements in both experimental and computational techniques will enable the application of better, model-informed assessments of pharmacodynamic DDIs in drug discovery, development, and therapeutics.
© 2019 The Authors Clinical Pharmacology & Therapeutics © 2019 American Society for Clinical Pharmacology and Therapeutics.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 30912119      PMCID: PMC6529235          DOI: 10.1002/cpt.1434

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  81 in total

1.  Tumor development under angiogenic signaling: a dynamical theory of tumor growth, treatment response, and postvascular dormancy.

Authors:  P Hahnfeldt; D Panigrahy; J Folkman; L Hlatky
Journal:  Cancer Res       Date:  1999-10-01       Impact factor: 12.701

Review 2.  A MOLECULAR BASIS FOR DRUG ACTION. THE INTERACTION OF ONE OR MORE DRUGS WITH DIFFERENT RECEPTORS.

Authors:  E J ARIUENS; A M SIMONIS
Journal:  J Pharm Pharmacol       Date:  1964-05       Impact factor: 3.765

Review 3.  A MOLECULAR BASIS FOR DRUG ACTION.

Authors:  E J ARIUENS; A M SIMONIS
Journal:  J Pharm Pharmacol       Date:  1964-03       Impact factor: 3.765

4.  Mixed immunotherapy and chemotherapy of tumors: modeling, applications and biological interpretations.

Authors:  L G de Pillis; W Gu; A E Radunskaya
Journal:  J Theor Biol       Date:  2005-09-08       Impact factor: 2.691

5.  Assessment of drug interactions relevant to pharmacodynamic indirect response models.

Authors:  Justin Earp; Wojciech Krzyzanski; Abhijit Chakraborty; Miren K Zamacona; William J Jusko
Journal:  J Pharmacokinet Pharmacodyn       Date:  2004-10       Impact factor: 2.745

Review 6.  Highly active antiretroviral therapy: current state of the art, new agents and their pharmacological interactions useful for improving therapeutic outcome.

Authors:  Giuseppe Barbaro; Andrea Scozzafava; Antonio Mastrolorenzo; Claudiu T Supuran
Journal:  Curr Pharm Des       Date:  2005       Impact factor: 3.116

7.  A mechanism-based disease progression model for comparison of long-term effects of pioglitazone, metformin and gliclazide on disease processes underlying Type 2 Diabetes Mellitus.

Authors:  Willem de Winter; Joost DeJongh; Teun Post; Bart Ploeger; Richard Urquhart; Ian Moules; David Eckland; Meindert Danhof
Journal:  J Pharmacokinet Pharmacodyn       Date:  2006-03-22       Impact factor: 2.745

8.  Cyclooxygenase inhibitors and the antiplatelet effects of aspirin.

Authors:  F Catella-Lawson; M P Reilly; S C Kapoor; A J Cucchiara; S DeMarco; B Tournier; S N Vyas; G A FitzGerald
Journal:  N Engl J Med       Date:  2001-12-20       Impact factor: 91.245

9.  Sequence effect of docetaxel and carboplatin on toxicity, tumor response and pharmacokinetics in non-small-cell lung cancer patients: a phase I study of two sequences.

Authors:  Maki Ando; Hideo Saka; Yuichi Ando; Hironobu Minami; Takafumi Kuzuya; Masashi Yamamoto; Atsushi Watanabe; Shuzo Sakai; Kaoru Shimokata; Yoshinori Hasegawa
Journal:  Cancer Chemother Pharmacol       Date:  2005-03-15       Impact factor: 3.333

10.  Pharmacodynamic interaction of recombinant human interleukin-10 and prednisolone using in vitro whole blood lymphocyte proliferation.

Authors:  Abhijit Chakraborty; William J Jusko
Journal:  J Pharm Sci       Date:  2002-05       Impact factor: 3.534

View more
  18 in total

1.  Network-Based Systems Analysis Explains Sequence-Dependent Synergism of Bortezomib and Vorinostat in Multiple Myeloma.

Authors:  Charvi Nanavati; Donald E Mager
Journal:  AAPS J       Date:  2021-08-17       Impact factor: 4.009

2.  FOLFIRINOX Pharmacodynamic Interactions in 2D and 3D Pancreatic Cancer Cell Cultures.

Authors:  Taylor J Allen-Coyle; Jin Niu; Eva Welsch; Neil T Conlon; Weylon Garner; Martin Clynes; Finbarr O'Sullivan; Robert M Straubinger; Donald E Mager; Sandra Roche
Journal:  AAPS J       Date:  2022-10-13       Impact factor: 3.603

3.  Cluster Gauss-Newton and CellNOpt Parameter Estimation in a Small Protein Signaling Network of Vorinostat and Bortezomib Pharmacodynamics.

Authors:  Jin Niu; Van Anh Nguyen; Mohammad Ghasemi; Ting Chen; Donald E Mager
Journal:  AAPS J       Date:  2021-10-07       Impact factor: 3.603

4.  Physical therapy exerts sub-additive and suppressive effects on intracerebral neural stem cell implantation in a rat model of stroke.

Authors:  Harmanvir Ghuman; Nikhita Perry; Lauren Grice; Madeline Gerwig; Jeffrey Moorhead; Franziska Nitzsche; Alexander John Poplawsky; Fabrisia Ambrosio; Michel Modo
Journal:  J Cereb Blood Flow Metab       Date:  2021-11-26       Impact factor: 6.960

Review 5.  Time-dependent enzyme inactivation: Numerical analyses of in vitro data and prediction of drug-drug interactions.

Authors:  Jaydeep Yadav; Erickson Paragas; Ken Korzekwa; Swati Nagar
Journal:  Pharmacol Ther       Date:  2019-12-11       Impact factor: 12.310

Review 6.  Role of the Synergistic Interactions of Environmental Pollutants in the Development of Cancer.

Authors:  Francisco Alejandro Lagunas-Rangel; Jenni Viivi Linnea-Niemi; Błażej Kudłak; Michael J Williams; Jörgen Jönsson; Helgi B Schiöth
Journal:  Geohealth       Date:  2022-04-01

7.  Targeting Beta-Blocker Drug-Drug Interactions with Fibrinogen Blood Plasma Protein: A Computational and Experimental Study.

Authors:  Michael González-Durruthy; Riccardo Concu; Laura F Osmari Vendrame; Ivana Zanella; Juan M Ruso; M Natália D S Cordeiro
Journal:  Molecules       Date:  2020-11-19       Impact factor: 4.411

Review 8.  Nanotechnology Therapy for Alzheimer's Disease Memory Impairment Attenuation.

Authors:  Samo Ribarič
Journal:  Int J Mol Sci       Date:  2021-01-22       Impact factor: 5.923

Review 9.  Zoology, chemical composition, pharmacology, quality control and future perspective of Musk (Moschus): a review.

Authors:  Kai Liu; Long Xie; Mao Deng; Xumin Zhang; Jia Luo; Xiaofang Li
Journal:  Chin Med       Date:  2021-06-19       Impact factor: 5.455

10.  Pharmacodynamic modeling of synergistic birinapant/paclitaxel interactions in pancreatic cancer cells.

Authors:  Jin Niu; Xue Wang; Jun Qu; Donald E Mager; Robert M Straubinger
Journal:  BMC Cancer       Date:  2020-10-23       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.